Genor Biopharma (Stock code: 6998.HK) announced today that the results of the LEONARDA-1 phase III clinical trial in advanced HR+/HER2- breast cancer will be posted for the first time at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from June 2 to June 6.

Genor Biopharma (Stock code: 6998.HK) announced today its 2022 annual financial results, business progress and other highlights in the past year.

The China National Medical Products Administration (NMPA) has officially accepted the new drug application for GB491 (Lerociclib cyclin-dependent kinase 4/6 inhibitor) in combination with Fluvestran as the treatment of HR+/HER2- locally advanced or metastatic breast cancer patients with disease progression following previous endocrine therapy.

Genor Biopharma (Stock code: 6998.HK) announced today that the first patient has been successfully dosed in a Phase I/II clinical trial of GB263T, a novel EGFR/cMET/cMET trispecific therapeutic antibody, in China for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.

With the theme of “Only the innovators can make steady progress”, the press conference of the 2021 Chinese Biopharma Companies Innovation TOP 100 Series Lists was held online on September 16, 2022. Genor Biopharma remained included in the Chinese Antibody Drug Companies Innovation TOP 30.